Evaluation of intervention to prevent hypomagnesemia in cervical cancer patients receiving combination cisplatin and radiation treatment

Supportive Care in Cancer

Volumn 17, Issue 9, 2009, Pages 1195-1201

  Hunter, Rodney J ^a   Pace, Makala B ^a   Burns, Kimberly A ^a   Burke, Catherine C ^a   Gonzales, Deborah A ^a   Webb, Nicki F ^a   Levenback, Charles F ^a   Jhingran, Anuja ^a   Parker, Crystal ^a   Munsell, Mark F ^a   Smith, Judith A ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cervical cancer; CisXRT therapy; Hypomagnesemia

Indexed keywords

CISPLATIN; MAGNESIUM SULFATE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; FEMALE; HUMAN; HYDRATION; HYPOMAGNESEMIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

ADULT; ANTINEOPLASTIC AGENTS; CISPLATIN; FEMALE; HUMANS; MAGNESIUM; MAGNESIUM DEFICIENCY; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; UTERINE CERVICAL NEOPLASMS;

EID: 68949211341     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-008-0574-2     Document Type: Article

References (15)

1. H Lager G Daugaard 1999 Cisplatin and hypomagnesemia Cancer Treat Rev 25 47 58
2. M Lam DJ Adelstein 1986 Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin Am J Kidney Dis 8 164 169
3. G Ariceta J Rodriguez-Soriano A Vallo 1997 Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis Med Pediatr Oncol 28 35 40
4. TRJ Evans CL Harper 1995 A randomised study to determine whether routine intravenous magnesium supplements are necessary in patients receiving cisplatin chemotherapy with continuous infusion 5 Fluorouracil Eur J Cancer 31A 174 178
5. PM Netten PHM de Mulder 1990 Intravenous magnesium supplementation during cisdiammine-dichloroplatinum administration prevents hypomagnesemia Ann Oncol 1 369 372
6. M Martin E Diaz-Rubio 1992 Intravenous and oral magnesium supplementations in the prophylaxis of cisplatinum induced hypomagnesemia Am J Clin Oncol 15 348 351
7. EE Vokes R Mick 1990 A randomised study comparing intermittent to continuous administration of magnesium aspartate hydrochloride in cisplatin induced hypomagnesemia Br J Cancer 62 1015 1017
8. RL Schilsky T Anderson 1979 Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin Ann Intern Med 90 929 931
9. G Daugaard 1990 Cisplatin nephrotoxicity: experimental and clinical studies Dan Med Bull 37 164 169
10. V Launay-Vacher JB Rey C Isnard-Bagnis G Derapy M Daouphars 2008 Prevention of cisplatin nephrotoxicity: state of the art and recommendations from European Society of Clinical Pharmacy Special Interest Group on Cancer Care Cancer Chemother Pharmacol 61 903 909
11. N Pabla Z Dong 2008 Cisplatin nephrotoxicity: mechanism and renoprotective strategies Kidney Int 73 994 1007
12. K Nakazato C Kim K Terajima S Murata H Fujitani K Nakanishi H Tajima T Kumazaki A Sakamoto 2007 Large volume loading to prevent cisplatin-induced nephrotoxicity during negative-balance isolated pelvic perfusion J Cancer Res Clin Oncol 133 741 747
13. H Lajer M Kristensen HH Hansen S Nielsen J Frokiaer LF Ostergaard S Christensen G Daugaard TE Jonassen 2005 Magnesium depletion enhances cisplatin-induced nephrotoxicity Cancer Chemother Pharmacol 56 535 542
14. AE Vickers K Rose R Fisher M Saulnier P Sahota P Bentley 2004 Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology Toxicol Pathol 32 577 590
15. H Lajer G Daugard 1999 Cisplatin and hypomagnesemia Cancer Treat Rev 25 47 58